MedPath

Prospective observational study for advanced lung cancer with interstitial lung disease

Not Applicable
Conditions
Advanced lung cancer with interstitial lung disease
Registration Number
JPRN-UMIN000019370
Lead Sponsor
Hamamatsu University School of Medicine
Brief Summary

Among 124 patients enrolled, 109 patients who received chemotherapy were analyzed. After registration, 23 patients developed AE-ILD. The logistic analysis revealed that lower %FVC significantly increased the risk of AE-ILD. Overall response rates/median overall survival times in non-small-cell lung cancer and small-cell lung cancer for the first-line chemotherapy were 41%/8.9??onths and 91%/12.2??onths, respectively.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
124
Inclusion Criteria

Not provided

Exclusion Criteria

1. Post-radiation fibrosis alone

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Safety, particulary for the frequency and severity of chemotherapy-induced acute exacerbation of interstitial lung disease
Secondary Outcome Measures
NameTimeMethod
Efficacy including response rate and progression-free survival
© Copyright 2025. All Rights Reserved by MedPath